Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objective and subjective comparison between the use of povidone-iodine 1% vs 5% as antiseptic in patients that need anti-VEGF intravitreal injection
Randomized, prospective clinical trial. One group was intervened with povidone-iodine at 5% and the other at 1% as antiseptic for anti-VEGF intravitreal injection. Each patient was evaluated before and after the injection of anti-VEGF for tear break up time, bulbar redness and ocular surface satining with fluorescein. Pain perception was also evaluated 15 minutes after the injection and 48 hours after.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Povidone-iodine 1% | Experimental | Povidone-iodine 1% was used as antiseptic during anti-VEGF intravitreal injection |
|
| Povidone-iodine 5% | Active Comparator | Povidone-iodine 5% was used as antiseptic during anti-VEGF intravitreal injection |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Change of normal concentration of povidone-iodine 5% to 1% | Procedure | Normal concentration of povidone-iodine during anti-VEGF intravitreal injection was 5%. That concentration was utilized in the control group, and 1% in the experimental group. |
| Measure | Description | Time Frame |
|---|---|---|
| Tear breaking rupture | NIKBUT was measured with Keratopgraph before and after intravitreal injection | Change from baseline measured to 15 minutes post-injection |
| Bulbar redness | Bulbar redness was measured with Keratopgraph before and after intravitreal injection | Change from baseline measured to 15 minutes post-injection |
| Measure | Description | Time Frame |
|---|---|---|
| Oxford scale | Oxford scale was measured with fluorescein stain before and after intravitreal injection | Change from baseline measured to 15 minutes post-injection |
| Pain analog scale | Pain using visual analog scale was measured 15 minutes and 48 hours after intravitreal injection |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| José Gerardo García-Aguirre | Asociación para Evitar la Ceguera en México I.A.P. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asociación para Evitar la Ceguera en México I.A.P. | Mexico City | Mexico City | 04030 | Mexico |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| D010146 | Pain |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Clinical, prospective, randomized trial. Pre anti-VEGF intravitreal injection, with OCULUS Keratopgrapph 5M topograph, non invasive tear breaking time, bulbar redness, and Oxford scale with fluorescein staining were measured. During anti-VEGF injection, tetracaíne was use as anestetic. Povidone-iodine 1% or 5% was randomized as antiseptic. After anti-VEGF intravitreal injection, patients were examined again for tear bkreaking time, bulbar redness and Oxford sacle, plus pain 15 minutes after injection. Finally, two days after the injection, patients were interviwed by telephone about their pain.
Not provided
Not provided
Patients did not know which percentage of povidone-iodine was utilized during their injection.
Tear breaking time and bulbar redness were automized results by Keraatopgrah. Oxford scale pre and post injection was staged by an investigator that did not know the group in which the patient was.
| Change from baseline measured to 15 minutes post-injection |
| D013568 |
| Pathological Conditions, Signs and Symptoms |